Connecticut readers taking prescription medication for depression may be interested to read of a recent recall from GlaxoSmithKline. A letter from the Food and Drug Administration prompted the large drug manufacturer to recall selected batches of the drug Paxil/Seroxat. The letter stated that certain lots of the drug had potentially been contaminated, making them dangerous and defective drugs.
The letter was prompted by an inspection of one of GSK's manufacturing facilities located overseas. It claims that certain batches of Paxil were tainted by pharmaceutical waste. It said that until the problem was corrected the FDA would not approve new applications containing GSK materials.